Experimental drug aims to stop leukemia return after transplant

NCT ID NCT04623216

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times

Summary

This study tested a drug called sabatolimab in 24 adults and teens with acute myeloid leukemia who still had small amounts of cancer cells after a stem cell transplant. The goal was to see if sabatolimab, alone or with another drug, could prevent the leukemia from coming back without causing severe side effects like graft-versus-host disease. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Münster, 48149, Germany

  • Novartis Investigative Site

    Bergamo, BG, 24127, Italy

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

Conditions

Explore the condition pages connected to this study.